Abstract
Infection with the human immunodeficiency virus type 1 (HIV) results in a chronic infection that progressively cripples the host immune defenses. HIV infection is associated with increased tryptophan (trp) catabolism by the cytokine-inducible enzyme indoleamine 2,3-dioxygenase (IDO). IDO has powerful immune suppressive activity, which could contribute to the immune dysfunction observed in HIV-infected patients. In this review we discuss the immune mechanisms that could mediate the HIV-induced increase of IDO activity (such as IFN-γ , IFN-α , CTLA-4/B7 and direct viral exposure). We then consider the current knowledge of IDO-mediated immune suppressive mechanisms with regard to different cell types (CD4+ T cells, CD8+ T cells, natural killer cells, B cells and regulatory T cells), from the perspective of their potential consequences for the HIV-infected host. HIV-induced, IDO-mediated trp catabolism may contribute to the perpetuation of HIV infection into its chronic phase by dampening efficient immune anti-viral responses. Therapeutic approaches aimed at manipulating this powerful immune suppressive mechanism might be considered in the setting of HIV infection.
Keywords: Indoleamine 2,3-dioxygenase, HIV, immune suppression
Current Drug Metabolism
Title: How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation
Volume: 8 Issue: 3
Author(s): Adriano Boasso and Gene M. Shearer
Affiliation:
Keywords: Indoleamine 2,3-dioxygenase, HIV, immune suppression
Abstract: Infection with the human immunodeficiency virus type 1 (HIV) results in a chronic infection that progressively cripples the host immune defenses. HIV infection is associated with increased tryptophan (trp) catabolism by the cytokine-inducible enzyme indoleamine 2,3-dioxygenase (IDO). IDO has powerful immune suppressive activity, which could contribute to the immune dysfunction observed in HIV-infected patients. In this review we discuss the immune mechanisms that could mediate the HIV-induced increase of IDO activity (such as IFN-γ , IFN-α , CTLA-4/B7 and direct viral exposure). We then consider the current knowledge of IDO-mediated immune suppressive mechanisms with regard to different cell types (CD4+ T cells, CD8+ T cells, natural killer cells, B cells and regulatory T cells), from the perspective of their potential consequences for the HIV-infected host. HIV-induced, IDO-mediated trp catabolism may contribute to the perpetuation of HIV infection into its chronic phase by dampening efficient immune anti-viral responses. Therapeutic approaches aimed at manipulating this powerful immune suppressive mechanism might be considered in the setting of HIV infection.
Export Options
About this article
Cite this article as:
Boasso Adriano and Shearer M. Gene, How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation, Current Drug Metabolism 2007; 8 (3) . https://dx.doi.org/10.2174/138920007780362527
DOI https://dx.doi.org/10.2174/138920007780362527 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Effects on Drug Targets: Inhibition of Enzymes by Neuroleptics, Antimycotics,Antibiotics and Other Drugs on Human Pathogenic Amoebas and their Antiproliferative Effects
Recent Patents on Anti-Infective Drug Discovery 123I-FP-CIT Brain SPECT Findings in Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Current Radiopharmaceuticals Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Novel Opportunities to Study and Block Interactions between Viruses and Cell Surface Heparan Sulfates by using Dispirotripiperazines
Letters in Drug Design & Discovery Drug Targets from Human Pathogenic Amoebas: Entamoeba histolytica,Acanthamoeba polyphaga and Naegleria fowleri
Infectious Disorders - Drug Targets Intravenous Immunoglobulin Preparations and Autoimmune Disorders: Mechanisms of Action
Current Pharmaceutical Biotechnology Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus
Current Pharmaceutical Design Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Inhibitors of Cholinesterases in Pharmacology: the Current Trends
Mini-Reviews in Medicinal Chemistry Neuro-Immune-Endocrine Mechanisms During Septic Shock: Role For Nitric Oxide in Vasopressin and Oxytocin Release
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Adenosine Dysfunction in Epilepsy and Associated Comorbidities
Current Drug Targets Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches
CNS & Neurological Disorders - Drug Targets